Celera Signs DNA Sciences to Database Subscription Deal
Rockville, MD and Freemont, CA - June 15, 2001
Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that DNA Sciences, Inc., an integrated genetics discovery company, has signed a multi-year subscription agreement with Celera. DNA Sciences will access the Celera Discovery System™ (CDS) to use Celera's database products, bioinformatics systems, and other discovery tools in their research on the genetic basis of common disease susceptibility and treatment response. Financial terms of the agreement were not disclosed.
“As a leader in genetics research ranging from DNA sequencing and genotyping to discovery and development efforts, we are pleased that DNA Sciences recognizes the power of our annotated genomic data and bioinformatics capabilities and has chosen to subscribe to CDS,” said J. Craig Venter, Ph.D., Celera's president and chief scientific officer. “As the amount of genomic data expands and as researchers look for ways to manage and interpret these data, we believe that CDS will continue to be an integral component to biomedical research programs worldwide including Celera’s own internal R&D efforts.”
“We believe that access to the mouse and human genome and SNP databases will be valuable to our discovery of gene variants associated with common disease susceptibility and treatment response,” said Hugh Y. Rienhoff Jr., M.D., chairman and chief executive officer of DNA Sciences, Inc.
The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.
“Our scientists will immediately apply these tools to our disease programs, particularly those studies where we have identified regions of interest in the genome,” said Raymond L. White, Ph.D., chief scientific officer at DNA Sciences. “This information will make a tremendous contribution to our discovery efforts in common disease susceptibility and response to drug treatment.”
About DNA Sciences
DNA Sciences, Inc. is an integrated genetics discovery company focused on identifying the genetic basis of common disease susceptibility, disease progression and response to drug treatment. DNA Sciences, Inc. is based in Fremont, Calif., and was founded in May 1998. DNA Sciences research is based on the idea that the genetic variants involved in common diseases are of low to moderate penetrance, i.e., only some carriers will develop the disease. Many of these moderately-penetrant gene variants may be difficult to detect using classical methods of discovery. DNA Sciences has developed new methods specifically designed to identify these types of gene variants. These gene variants will help patients and their physicians manage health more effectively through disease risk-reduction, earlier diagnosis and more specific therapies. DNA Sciences company recruits samples for its research through academic and corporate collaborations, as well as the DNA Sciences Gene Trust Projectsm. Visit DNA Sciences website at www.dna.com.
Applera Corporation, comprises two operating groups. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation diagnostic and therapeutic discovery company. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for subscribers and for its own internal product development. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.